Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy presented as a 100 mg/5 ml solution for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Accord is used in the treatment of cancers that involve the colorectal pathway and related solid tumours.

- Colorectal cancer: enhances the efficacy of combination chemotherapy regimens and helps achieve tumour shrinkage. - Gastric cancer: contributes to disease control when used with other agents. - Pancreatic cancer: used as part of multi‑drug protocols to improve response rates. - Ovarian cancer: added to standard regimens to increase progression‑free survival. - Metastatic adenocarcinoma: employed in combination therapy to extend overall survival.

Oxaliplatin Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Fatigue: generalised tiredness during treatment cycles. - Diarrhoea: loose stools that may require supportive care. - Thrombocytopenia: reduced platelet count increasing bleed risk.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Acute neurotoxicity: sudden onset of muscle cramps or spasms. - Hemolytic‑uremic syndrome: rare renal and hematologic complication. - Cardiotoxicity: arrhythmias or myocardial injury in susceptible patients. - Neutropenic sepsis: life‑threatening infection due to low neutrophil counts.

When using Oxaliplatin Accord, clinicians should consider several safety measures to minimise risks.

- Renal function: assess baseline creatinine and monitor during therapy. - Neuropathy monitoring: evaluate sensory changes before each cycle. - Hematologic surveillance: perform regular CBCs to detect cytopenias. - Hypersensitivity risk: be prepared to manage acute allergic reactions. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal harm. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin Accord can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use with high‑dose cis‑cis may increase kidney injury risk. - Anticoagulants: may potentiate bleeding when thrombocytopenia is present. - Live vaccines: immunosuppression can reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - CYP450 inducers: may affect plasma levels of co‑administered drugs. - Antacids containing magnesium or aluminum: can alter drug stability in infusion solutions. - Radiotherapy: combined neurotoxicity risk requires dose adjustments.